Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Co. is developing two drug candidates: NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. We show 11 historical shares outstanding datapoints in our NVCT shares outstanding history coverage, used to compute NVCT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NVCT market cap history over the course of time is important for investors
interested in comparing NVCT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NVCT versus a peer is one thing; comparing
NVCT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NVCT can fluctuate over the course of history.
With this page we aim to empower investors researching NVCT by allowing them to research the NVCT market cap history. |
Free NVCT Email Alerts:
Video: The Importance of Market Cap
